Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)
Status:
Terminated
Trial end date:
2017-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if patients suffering from diabetic peripheral
neuropathic pain treated with ranolazine will have a greater reduction in pain compared to
placebo.
Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical
animal model of neuropathic pain, the investigators hypothesize that subjects randomized to
ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.